Ting Zhang

Dr. Ting Zhang

Save Sight Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2008, Australia

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2019 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
SLSamuel W Lukowski
Samuel W Lukowski
CLCamden Y Lo
Camden Y Lo
ASAlexei A Sharov
Alexei A Sharov
QNQuan Nguyen
Quan Nguyen
LFLyujie Fang
Lyujie Fang
Raymond C. B. WongRaymond C. B. Wong
Raymond C. B. Wong
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

30 April 2019 in eLife
Verified
Journal Article
Open access
TZTing Zhang
Ting Zhang
Ling ZhuLing Zhu
Ling Zhu
Michele MadiganMichele Madigan
Michele Madigan
WLWei Liu
Wei Liu
WSWeiyong Shen
Weiyong Shen
MGMark C Gillies
Mark C Gillies
The human macula is more susceptible than the peripheral retina to developing blinding conditions such as age-related macular degeneration, diabetic retinopathy. A key difference between them may be the nature of their Müller cells. We found primary cultured Müller cells from macula and peripheral retina display significant morphological and transcriptomic differences. Macular Müller cells expressed more phosphoglycerate dehydrogenase (PHGDH, a rate-limiting enzyme in serine synthesis) than peripheral Müller cells. The serine synthesis, glycolytic and mitochondrial function were more activated in macular than peripheral Müller cells. Serine biosynthesis is critical in defending against oxidative stress. Intracellular reactive oxygen species and glutathione levels were increased in primary cultured macular Müller cells which were more susceptible to oxidative stress after inhibition of PHGDH. Our findings indicate serine biosynthesis is a critical part of the macular defence against oxidative stress and suggest dysregulation of this pathway as a potential cause of macular pathology.

11 May 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
YCYingying Chen
Yingying Chen
NCNathan J. Coorey
Nathan J. Coorey
MZMeixia Zhang
Meixia Zhang
SZShaoxue Zeng
Shaoxue Zeng
Michele MadiganMichele Madigan
Michele Madigan
TZTing Zhang
Ting Zhang
The human retina, which is part of the central nervous system, has exceptionally high energy demands that requires an efficient metabolism of glucose, lipids, and amino acids. Dysregulation of retinal metabolism disrupts local energy supply and redox balance, contributing to the pathogenesis of diverse retinal diseases, including age-related macular degeneration, diabetic retinopathy, inherited retinal degenerations, and Macular Telangiectasia. A better understanding of the contribution of dysregulated metabolism to retinal diseases may provide better therapeutic targets than we currently have.

19 November 2020 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
SZShaoxue Zeng
Shaoxue Zeng
TZTing Zhang
Ting Zhang
MMMichele C. Madigan
Michele C. Madigan
NFNilisha Fernando
Nilisha Fernando
RARiemke Aggio-Bruce
Riemke Aggio-Bruce
LZLing Zhu
Ling Zhu
Interphotoreceptor retinoid-binding protein (IRBP), also known as retinol binding protein 3 (RBP3), is a lipophilic glycoprotein specifically secreted by photoreceptors. Enriched in the interphotoreceptor matrix (IPM) and recycled by the retinal pigment epithelium (RPE), IRBP is essential for the vision of all vertebrates as it facilitates the transfer of retinoids in the visual cycle. It also helps to transport lipids between the RPE and photoreceptors. The thiol-dependent antioxidant activity of IRBP maintains the delicate redox balance in the normal retina. Thus, its dysfunction is suspected to play a role in many retinal diseases. We have reviewed here the latest research on IRBP in both retinal health and disease, including the function and regulation of IRBP under retinal stress in both animal models and the human retina. We have also explored the therapeutic potential of targeting IRBP in retinal diseases. Although some technical barriers remain, it is possible that manipulating the expression of IRBP in the retina will rescue or prevent photoreceptor degeneration in many retinal diseases.

9 January 2021 in Protein & Cell
Verified
Journal Article
Open access
PDF file
YWYujia Wang
Yujia Wang
YZYu Zhao
Yu Zhao
ZZZixian Zhao
Zixian Zhao
DLDan Dan Li
Dan Dan Li
HNHao Nie
Hao Nie
WZWei Zuo
Wei Zuo

23 May 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
JZJialing Zhang
Jialing Zhang
TZTing Zhang
Ting Zhang
SZShaoxue Zeng
Shaoxue Zeng
XZXinyuan Zhang
Xinyuan Zhang
FZFanfan Zhou
Fanfan Zhou
Ling ZhuLing Zhu
Ling Zhu
Age-related diseases, such as Parkinson’s disease, Alzheimer’s disease, cardiovascular diseases, cancers, and age-related macular disease, have become increasingly prominent as the population ages. Oxygen is essential for living organisms, but it may also cause disease when it is transformed into reactive oxygen species via biological processes in cells. Most of the production of ROS occurs in mitochondrial complexes I and III. The accumulation of ROS in cells causes oxidative stress, which plays a crucial role in human ageing and many diseases. Nuclear factor-erythroid 2-related factor 2 (Nrf2) is a key antioxidant transcription factor that plays a central role in many diseases and ageing in general. It regulates many downstream antioxidative enzymes when cells are exposed to oxidative stress. A basic-region leucine zipper (bZIP) transcription factor, MAF, specifically the small MAF subfamily (sMAFs), forms heterodimers with Nrf2, which bind with Maf-recognition elements (MAREs) in response to oxidative stress. The role of this complex in the human retina remains unclear. This review summarises the current knowledge about Nrf2 and its downstream signalling, especially its cofactor—MAF, in ageing and diseases, with a focus on the retina. Since Nrf2 is the master regulator of redox homeostasis in cells, we hypothesise that targeting Nrf2 is a promising therapeutic approach for many age-related diseases.